Innova Captab, a pharmaceutical company, has reported robust financial performance for the fourth quarter (Q4FY24) and the full fiscal year 2024 (FY24).
Q4FY24 Financial Highlights:
Revenue from Operation: ₹262.63 crore (9.0% growth YoY)
EBITDA: ₹43.76 crore (48.7% growth YoY)
Profit After Tax (PAT): ₹28.72 crore (66.5% growth YoY)
FY24 Financial Highlights:
Total Income: ₹1,093.79 crore (16.9% growth over FY23)
Revenue from Operation: ₹1,081.31 crore (16.7% growth over FY23)
EBITDA: ₹166.94 crore (35.9% increase over FY23)
Profit After Tax (PAT): ₹94.35 crore (38.9% growth over FY23)
Key Points:
Strong Growth: Innova Captab witnessed significant growth in revenue and profitability in both Q4FY24 and FY24.
Increased Demand: The growth was driven by increased demand for its products in both domestic and international markets.
Expansion Plans: The company is expanding its manufacturing capacity and product portfolio to cater to the growing demand.
New Acquisitions: Innova Captab recently acquired Sharon Bio-Medicine, which is expected to further boost its growth trajectory.
Management Commentary:
Vinay Lohariwala, Managing Director of Innova Captab, expressed optimism about the company's future prospects, highlighting the positive traction in all business areas and the expected healthy growth rate in the coming years. He also mentioned the upcoming Jammu facility and the recent Sharon acquisition as key factors that will contribute to maintaining the company's growth momentum.
For further information, you can refer to the following resources:
ICICI Direct Analysis: https://www.icicidirect.com/research/equity/rapid-results/innova-captab-ltd
5paisa Share Price: https://www.5paisa.com/stocks/innovacap-share-price
Innova Captab Investor Relations: https://www.innovacaptab.com/investor-relations.php
Comments